What is iRhythm Technologies?
Founded in 2006, iRhythm Technologies operates at the intersection of medical device manufacturing and advanced data science. The company specializes in the development of wearable biosensors that capture continuous cardiac data, which is subsequently processed through proprietary, cloud-based algorithms. By converting millions of heartbeats into precise, actionable clinical information, iRhythm provides healthcare providers with the tools necessary for early disease detection, prediction, and prevention.
The firm maintains a robust presence across North America, Europe, and the Asia-Pacific region, offering a comprehensive suite of services that cater to both clinical providers and individual patients. Through its mobile applications and digital platforms, iRhythm has effectively bridged the gap between traditional medical diagnostics and modern, data-driven healthcare delivery, positioning itself as a critical component of the contemporary digital health ecosystem.
How much funding has iRhythm Technologies raised?
iRhythm Technologies has raised a total of $337.2M across 10 funding rounds:
Other Financing Round
$10M
Series C
$22M
Private Equity
$12.2M
Debt
$3.5M
Series D
$16M
Series E
$17M
Stock Offering
$123M
Stock Offering
$115M
Other Financing Round (2010): $10M supported by Mohr Davidow Ventures, St. Jude Medical, and Synergy Life Science Partners
Series C (2011): $22M featuring Synergy Life Science Partner, St. Jude Medical, New Leaf Venture Partners, Mohr Davidow Ventures, Kaiser Permanente Ventures, and Stanford University
Private Equity (2012): $12.2M backed by Synergy Life Science Partner, New Leaf Venture Partners, Kaiser Permanente Ventures, and Mohr Davidow Ventures
Debt (2012): $3.5M, investors not publicly disclosed
Series D (2013): $16M led by Norwest Venture Partners, Synergy Life Science Partners, New Leaf Venture Partners, and Kaiser Permanente Ventures
Series E (2014): $17M supported by Norwest Venture Partners and Novo A/S
Stock Issuance/Offering (2016): $123.1M, investors not publicly disclosed
Stock Issuance/Offering (2019): $115M, investors not publicly disclosed
Key Investors in iRhythm Technologies
Norwest Venture Partners
Founded in 1961, Norwest Venture Partners is a global, multi-stage venture capital and growth equity investment firm headquartered in Palo Alto, California.
Kaiser Permanente Ventures
Kaiser Permanente Ventures is a national leader in strategic venture investing in healthcare, focusing on advancing innovation and integrating new approaches into established organizations.
New Leaf Venture Partners
New Venture Partners LLC is a global venture capital firm dedicated to corporate technology spinouts, providing a bridge between technology corporations and traditional venture capital.
What's next for iRhythm Technologies?
Looking ahead, iRhythm Technologies is well-positioned to leverage its substantial capital base to deepen its market penetration and expand its technological capabilities. The current enterprise-level funding context suggests a focus on scaling operations and potentially integrating more sophisticated predictive analytics into its existing product pipeline. As the company continues to refine its biosensor technology, it is likely to prioritize strategic partnerships with major healthcare delivery systems to further embed its solutions into standard clinical workflows. The focus remains on maintaining its competitive edge in the cardiac monitoring space while exploring new frontiers in preventative medicine and remote patient management.
See full iRhythm Technologies company page
